🇺🇸·Jun 22CRO
Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test
Publisher
L
Labcorp Drug Development
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Labcorp Drug Development
- Region
- USA
- Scope
- CRO
- Published
- June 22, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on ir.labcorp.com
Leave the platform to read the original full article on the publisher site.
Source: Labcorp Drug Development
Scope: CRO
Related coverage
More related coverage
Becton Dickinson (BD)/4h ago
BD Reports Third Quarter Fiscal 2026 Financial Results
EOF Greece/4h ago
Σύσκεψη στον ΕΟΦ για την ομαλή λειτουργία της εφοδιαστικής αλυσίδας των φαρμάκων.
Pharmaceutical Executive/5h ago
Mergers as Strategic Architecture: Rethinking How to Evaluate the AstraZeneca–BMS Rumors
fiercebiotech.com/5h ago